The Use of Salivary Protein Secretions as an<i>In Vivo</i>Model to Study Mantel Cell Lymphoma Progression and Treatment

Streckfus, Charles F.; Romaguera, Jorge; Guajardo-Streckfus, Cynthia

doi:10.3109/07357907.2013.820319

Cited by 8 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite numerous research studies on salivary biomarkers, saliva monitoring still is in its infancy. Streckfus et al [ 87 ] observed pre-, peri- and post-chemotherapy variations in the salivary protein profile of an individual with Mantel cell lymphoma, suggesting the use of saliva for controlling disease progression.…”

Section: Systemic Cancer and Salivamentioning

confidence: 99%

Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity

Rapado‐González

Majem

Muinelo‐Romay

et al. 2016

IJMS

View full text Add to dashboard Cite

Abstract:The analysis of saliva as a diagnostic approach for systemic diseases was proposed just two decades ago, but recently great interest in the field has emerged because of its revolutionary potential as a liquid biopsy and its usefulness as a non-invasive sampling method. Multiple molecules isolated in saliva have been proposed as cancer biomarkers for diagnosis, prognosis, drug monitoring and pharmacogenetic studies. In this review, we focus on the current status of the salivary diagnostic biomarkers for different cancers distant to the oral cavity, noting their potential use in the clinic and their applicability in personalising cancer therapies.

show abstract

Section: Systemic Cancer and Salivamentioning

confidence: 99%

Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity

Rapado‐González

Majem

Muinelo‐Romay

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…In spite of the power of the t(11;14)(q1;q32) translocation as a hallmark of MCL, other disease markers would be valuable for both diagnosis and as potential treatment targets, warranting further study of CD148 in this tumor. A study directly assessing treatment response in MCL was performed by Streckfus et al . They characterized the proteome from specimens of saliva before, during, and after therapy for MCL .…”

Section: Biomarker Discovery In Lymphoma Patient Samples By a Proteommentioning

confidence: 99%

“…A study directly assessing treatment response in MCL was performed by Streckfus et al . They characterized the proteome from specimens of saliva before, during, and after therapy for MCL . 2D DIGE and subsequent identification by LC‐MS/MS was used to identify differences in protein profiles from one patient with a sample at time of recurrence (pretreatment) and a second sample at time of remission (posttreatment).…”

Section: Biomarker Discovery In Lymphoma Patient Samples By a Proteommentioning

confidence: 99%

Proteomic approaches to the study of malignant lymphoma: Analyses on patient samples

Ludvigsen

Hamilton-Dutoit

d’Amore

et al. 2015

Proteomics Clinical Apps

View full text Add to dashboard Cite

We describe the application of proteomic techniques for protein profiling and biomarker discovery in malignant lymphoma. Hematologic malignancies are primarily characterized by their clinical, morphological, immunophenotypical, and molecular-genetic features. However, when based on these parameters, apparently identical lymphomas may show distinct clinical courses, suggesting underlying biological heterogeneity. Recent proteomic analyses have identified differences in protein expression both with regard to subclassification of the malignant lymphoma entities, as well as in correlation with clinical outcome. In this review, studies on quantification of differential protein expression in and between malignant lymphoma entities are included. Studies are included that are based on patient samples, that is, serum/plasma or cytological specimens, as well as intact tumor tissues, together with studies that focus on tumor cells alone, or in conjunction with the tumor microenvironment. For biomarker discovery in malignant lymphoma, these approaches are used to uncover the underlying biological mechanisms and identify proteins with potential diagnostic and prognostic utility, either as predictive biomarkers or as novel future treatment targets.

show abstract

“…The author would like to add two more items: (1) ascertain methods to determine the efficacy of treatment and (2) ascertain methods to determine that the treated patient is not only in clinical remission, but in molecular remission as well [13,14]. The latter action items would assure successful treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Taken together, there remains a necessity to identify novel approaches that improve breast cancer screening and early detection. This, in turn, reduces the problems of over-diagnosis and over-treatment and can detect cancers at a point where interventions maybe more effective [1][2][3][4][5][6][7][8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Salivary Biomarkers to Assess Breast Cancer Diagnosis and Progression: Are We There Yet?

Streckfus¹

2019

Saliva and Salivary Diagnostics

View full text Add to dashboard Cite

Technological developments are propelling medical diagnostics forward at unprecedented rates. Advancements in genomic, proteomics and cellomics are leading the way for diagnostic tests that will be capable of rapid multi-analyte detection in both laboratory and non-laboratory settings. Currently, proof-of-principle has been demonstrated for salivary biomarkers, whose up and down regulation has been shown to correlate strongly with breast cancer among women. Consequently, the rationale for this chapter is to review the medical literature and present the current research focused on the use of saliva as a diagnostic medium for the study of early breast cancer progression.

show abstract

The Use of Salivary Protein Secretions as anIn VivoModel to Study Mantel Cell Lymphoma Progression and Treatment

Cited by 8 publications

References 11 publications

Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity

Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity

Proteomic approaches to the study of malignant lymphoma: Analyses on patient samples

Salivary Biomarkers to Assess Breast Cancer Diagnosis and Progression: Are We There Yet?

Contact Info

Product

Resources

About